CSL Limited is an established global leader in plasma-derived therapies. Operating globally in large and growing markets, it is delivering innovative life-saving medicines to patients in more than 100 countries. Trading at good levels, it could be among the best growth stocks to buy now.
CSL Limited (ASX: CSL)
CSL Limited is a leading global player in plasma-derived therapies, influenza vaccines, and iron therapies, operating in over 100 countries. The company, one of the high quality dividend paying stocks, reported a strong financial performance in FY24, achieving a Net Profit After Tax (NPAT) of US$2.64 billion and declaring a total dividend of US$2.64 per share (approximately A$4.00). This reflects robust execution in growing markets underpinned by significant investments in infrastructure, R&D, and talent over the past decade.
CSL has strategically expanded its operational capacity with notable milestones, including the completion of the Broadmeadows fractionation facility, enhancements to CSL Behring sites in Switzerland and Germany, and upgrades to the Seqirus influenza vaccine facility in the U.S. The company also advanced its R&D capabilities with new facilities in Germany, the U.S., and Melbourne, Australia. These investments position CSL to support long-term demand growth, although the business now anticipates a less capital-intensive growth phase while remaining prepared for additional capacity expansion as needed.
The company’s leadership emphasizes the importance of capability-building, focusing on risk management, scientific expertise, and emerging domains like digital and cybersecurity. Recent additions to the Board, Samantha Lewis and Elaine Sorg, bring valuable expertise in financial governance and global biopharmaceutical operations, respectively. These appointments align with CSL's strategy to navigate the complexities of its global footprint. R&D remains a cornerstone of CSL’s growth, with continued focus on plasma, immunoglobulin, and vaccine platforms. However, the inherent risks of research have led to the discontinuation of certain clinical trials, reflecting disciplined portfolio management. Successful innovations, such as HEMGENIX for Hemophilia B, underline the company’s ability to address unmet medical needs despite these challenges.
CSL Vifor, acquired over two years ago, represents a significant long-term growth opportunity, although near-term performance has been impacted by unforeseen challenges. Management remains confident in its strategic alignment with CSL’s broader business and its potential to deliver sustained growth. In summary, CSL's investments in capacity, talent, and innovation have established a strong foundation for sustainable growth. One of the high growth stocks, it remains well-positioned to capitalize on rising demand in its core therapeutic areas, while its disciplined approach to R&D and operational excellence supports long-term value creation for shareholders.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.